Navigation Links
EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
Date:6/18/2008

Experienced Biotech Business Development and Investment Banker Enhances

EntreMed's Senior Management Team

ROCKVILLE, Md., June 18 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the appointment of Mr. Thomas H. Bliss, Jr. as Senior Vice President, Corporate and Business Development. Mr. Bliss has been elected an executive officer by EntreMed's Board of Directors and will report to the Company's President and Chief Executive Officer, Mr. James S. Burns.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Most recently the Executive Director, Licensing at Amgen, Mr. Bliss brings nearly 20 years biotechnology business development and healthcare investment banking experience to EntreMed. In his most recent role at Amgen, Mr. Bliss was responsible for international licensing, licensing operations oversight and the coordination and communication of Amgen's China/India Research Activities Initiative. Previous to that, Mr. Bliss was responsible for directing all Amgen acquisition activity, including the acquisition of Abgenix. Prior to joining Amgen in 2004, Mr. Bliss served as Vice President, BioPharmaceuticals Business Development at Baxter BioScience, where he directed all licensing and acquisition activities.

Mr. Bliss' career in life science business development began in 1994 with Johnson & Johnson where he provided analytical support for all franchises and participated in the creation of billion dollar cardiovascular access and orthopedic businesses. The first
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
2. EntreMed Appoints Senior Vice President of Research and Development
3. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
4. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
5. EntreMed to Present at BIO CEO and Investor Conference
6. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
7. EntreMed Announces 2008 Corporate and Clinical Program Priorities
8. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
9. EntreMed Receives Nasdaq Deficiency Notice
10. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
11. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Rhinebeck, NY (PRWEB) May 17, 2013 ... by Topical BioMedics, Inc., has been listed among ... 2013 in an initiative conducted by "U.S. News" ... product has earned the “No. 1 Pharmacists ... with 17 other national OTC brands, and is ...
(Date:5/17/2013)... release is available in German . ... well: with the naked eye, you can see which branch ... the blur of branches through the telephoto lens for high-magnification ... researchers who are looking to study proteins, the active biomolecules ... Zurich,s Institute for Molecular Systems Biology, and her colleagues have ...
(Date:5/17/2013)... , May 17, 2013 ... the most innovative thought leaders of the medical ... Manufacturing East conference and expo, from June 18-20 ...      (Photo: http://photos.prnewswire.com/prnh/20130517/613829 ) , ... to deliver industry professionals practical presentations and implementable ...
(Date:5/17/2013)... MIAMI , May 17, 2013  Insero Health, ... medical needs in epilepsy and related neurological disorders, is ... of its lead compound INS001 in patients with drug-resistant ... Drug and Device Trials (AED) Xll meeting by Dr. ... epileptologist and Chairman of Insero,s Scientific Advisory Board.  In ...
Breaking Biology Technology:Pharmacists' Picks: Topical BioMedics' Topricin Listed on Top Recommended OTC Health Products 2Proteome atlas for the tuberculosis pathogen 2Proteome atlas for the tuberculosis pathogen 3MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2
... April 18 FASgen, Inc. presented at the ... on FAS31, FASgen,s lead,compound for ovarian cancer. FAS31 ... enzyme that is highly expressed in many human ... is cytotoxic to a,variety of human xenograft models ...
... Inc. (Nasdaq:,EVVV) will release its 2008 first quarter financial ... hours., The company will host a conference call ... a.m. ET). ev3 management will review its first quarter,operating ... answer,session., The conference call will be available to ...
... BrainCells Inc. (BCI), a,biopharmaceutical company utilizing its ... the growth of new neurons for the treatment,of ... it raised an,additional $20 million in an extension ... $50 million. New investor, New Enterprise Associates (NEA),along ...
Cached Biology Technology:FASgen, Inc. Presents Ovarian Cancer Efficacy and Toxicology Data to the American Association for Cancer Research 2REVISED: BrainCells Inc. Expands Series B Financing to $50 Million 2
(Date:5/16/2013)... May 16, 2013 Integrated Biometrics patented ... a custom thin film transistor camera introduces Sherlock, ... roll image in the smallest and lightest form ... Appendix F Mobile ID FAP 45, Certified scanner ... in size and weight when compared to optical ...
(Date:5/16/2013)... where the entirety of an individual,s DNA is examined ... can cause health problems is a massively useful technology ... major ethical problems if used incorrectly, say new recommendations ... on line today (16 May 2013) in the ... on whole genome and on exome* sequencing and analysis ...
(Date:5/16/2013)... , May 16, 2013 Reportlinker.com ... is available in its catalogue: ... Opportunities, 2018 http://www.reportlinker.com/p01181929/Global-Biometric-Systems-Market-Forecast--Opportunities-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Security_Systems ... old security practises such as photographs, passwords ... of biometric technologies in last few years. ...
Breaking Biology News(10 mins):European Society of Human Genetics urges caution over use of new genetic sequencing techniques 2Global Biometric Systems Market Forecast & Opportunities, 2018 2Global Biometric Systems Market Forecast & Opportunities, 2018 3Global Biometric Systems Market Forecast & Opportunities, 2018 4Global Biometric Systems Market Forecast & Opportunities, 2018 5Global Biometric Systems Market Forecast & Opportunities, 2018 6Global Biometric Systems Market Forecast & Opportunities, 2018 7
... the heart that can cause congestive heart failure. ... of the myocardium to regenerate and self-repair. Douglas ... the existence of a previously unrecognized subset of ... for myocardial tissue regeneration following myocardial infarction. , ...
... The World Health Organization (WHO) warned about increased ... dengue fever across tsunami-affected areas in Southeast Asia. ... region on 26 December, the organization is strengthening ... for mosquito vectors to multiply to sufficient levels, ...
... chemical has been found by Health Canada and the ... especially canned or bottled foods. A new study by ... Perez Locas explains the presence of this chemical in ... published in the October, 2004 issue of Journal of ...
Cached Biology News:WHO Warns Of Increased Risk Of Vector-borne Diseases In Tsunami-affected Areas 2WHO Warns Of Increased Risk Of Vector-borne Diseases In Tsunami-affected Areas 3WHO Warns Of Increased Risk Of Vector-borne Diseases In Tsunami-affected Areas 4